DSM is active in nutritional and pharma ingredients, performance materials and industrial chemicals. DSM’s products are used in a wide range of end-markets and applications, such as human and animal nutrition and health, personal care, pharmaceuticals, automotive and transport, coatings and paints, housing and electrics and electronics.
DSM has sales of over Euro9bn and around 22,000 employees (2010). The company is headquartered in the Netherlands, with locations in Europe, US, Asia, Africa, and Australia.
Download the The ICIS Top 100 Chemical Companies listing here
In December 2010, DSM agreed to buy Martek Biosciences. For more on this please see DSM makes $1.09bn bid for US nutritional supplements maker Martek on ICIS news
Also in December 2010, DSM completed the sale of its DSM Special Products business to Emerald Performance Materials. For more on this please see DSM completes sale of DSM Special Products to private-equity firm on ICIS news
In December 2010, DSM reached an agreement to sell off the remaining part of DSM Elastomers to LANXESS. For more on this please see DSM sells elastomers business to LANXESS, completes divestment on ICIS news
Also in December 2010, DSM said it intends to buy a 51% stake in AGI. For more on this please see DSM plans to buy 51% stake in Taiwan UV curable resins firm AGI on ICIS news
In September 2010, DSM acquired Microbia for an undisclosed fee. For more on this please see DSM acquires US-based biotechnology firm Microbia on ICIS news
In June 2010, DSM completed the sale of DSM Agro and DSM Melamine to Orascom Construction Industries (OCI). For more on this please see DSM completes sale of fertilizer, melamine units to Orascom on ICIS news
Please see DSM completes takeover of Mitsubishi’s polyamide business on ICIS news
In January 2010, DSM Specialty Intermediates (DSI) said it will discontinue its operational activities by 31 December 2010. For more on this please see DSM Specialty Intermediates to stop operational activities on ICIS news.
In October 2009, DSM completed the sale of DSM Energie Holding (DSM Energy) to The Abu Dhabi National Energy Co PJSC (TAQA). For more on this story please see UAE's TAQA completes €285m purchase of Dutch DSM Energy and Dutch DSM to sell energy, urea businesses on ICIS news.
DSM's activities are grouped into four clusters: Nutrition, Pharma, Performance Materials and Industrial Chemicals.
The Nutrition cluster comprises of:
DSM Nutritional Products; and
DSM Food Specialties.
Its main customers are food, beverages, feed and flavour/fragrance companies. The activities in this cluster include biotechnology (including fermentation, genomics and biocatalysis), organic chemistry and formulation technologies and on the company’s broad application knowledge.
The Pharma cluster comprises of:
DSM Pharmaceutical Products; and
DSM is a supplier to the pharmaceutical industry, it claims that around 40% of today’s top-selling medicines in the world contain ingredients developed and produced by DSM.
The Performance Materials cluster comprises of:
DSM Engineering Plastics;
DSM Resins; and
DSM Elastomers (expected to be divested early 2011).
Its products are used in a wide variety of end-use markets: the automotive industry, the aviation industry, the electrics and electronics industry, the sports and leisure industries, the coatings industry and the construction industry.
The Polymer Intermediates segment consists of:
DSM Fibre Intermediates
DSM is the global leader in the supply and production technology of caprolactam, the raw material for Nylon-6.
Base Chemicals and Materials
The Base Chemicals and Materials segment comprises of:
DSM produces basic materials for plastics and materials, high-grade construction materials for medical applications, cars and electronic appliances.
Back to company overview page
DSM states that after successfully completing its strategy “Vision 2005 Focus and Value” in 2006, it will focus on its five year strategy of “Vision 2010 Building on Strengths” in 2007. The new strategy will focus on accelerated growth and expansion of the specialty content of its portfolio, accelerated innovation, and expansion in emerging economies. The overall objective of the strategy is “strong value creation”. (Edited from: “Message from the chairman”, “Objectives Vision 2010 – Building on Strengths"). ICIS also provides you with key financial data listed in table form.
More about DSM Strategy & Financial Highlights
Get news on DSM plus the latest chemical news, information, data, market movements and analysis
in one place with ICIS news
Find details on other chemical companies and suppliers with
ICIS offers a range of FREE e-newsletters to ensure that you don't miss out on the latest development and key market intelligence in your industry. If you want the latest news sent to your inbox, sign up for ICIS e-newsletters today.
Find out more about current and planned chemical plants and projects by subscribing to our comprehensive database
INSIGHT: China may see major ethylene shortfall by 2019
"At $50-90/bbl for Brent, UBS estimates the internal rate of return (IRR) for China CTO/MTO projects range from 5-10% – mostly too low to justify inve
VIDEO: ICIS Special Report: Innovation is key to success